Download FREE Report Sample
Download Free sampleCutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Cutaneous Leishmaniasis Drugs Market contains market size and forecasts of Cutaneous Leishmaniasis Drugs in global, including the following market information:
Global Cutaneous Leishmaniasis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cutaneous Leishmaniasis Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Cutaneous Leishmaniasis Drugs companies in 2021 (%)
The global Cutaneous Leishmaniasis Drugs market was valued at 44 million in 2021 and is projected to reach US$ 58 million by 2028, at a CAGR of 3.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pentavalent Antimonials Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cutaneous Leishmaniasis Drugs include GSK, Novartis, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Albert David, Profounda, Knight Therapeutics and Pfizer and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cutaneous Leishmaniasis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cutaneous Leishmaniasis Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, by Type, 2021 (%)
Anti-Leishmanial/Antimicrobial Drugs
Global Cutaneous Leishmaniasis Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, by Application, 2021 (%)
Global Cutaneous Leishmaniasis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, By Region and Country, 2021 (%)
Competitor Analysis
The report also provides analysis of leading market participants including:
Further, the report presents profiles of competitors in the market, key players include:
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
